Suppr超能文献

苯丙酮尿症患者骨矿物质密度与骨折的系统评价

A systematic review of bone mineral density and fractures in phenylketonuria.

作者信息

Hansen Karen E, Ney Denise

机构信息

Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA,

出版信息

J Inherit Metab Dis. 2014 Nov;37(6):875-80. doi: 10.1007/s10545-014-9735-2. Epub 2014 Jul 9.

Abstract

INTRODUCTION

Our objective was to systematically review and analyze published data on bone mineral density (BMD) and fracture rates in patients with phenylketonuria (PKU), and relationships between BMD and phenylalanine levels.

METHODOLOGY

We searched PubMed, CINAHL, and Cochrane databases from January 1966 to November 2013 for studies of spine BMD or fracture in PKU and control subjects. We excluded studies assessing skeletal health by ultrasound or peripheral quantitative computer tomography. Both authors reviewed abstracts for inclusion, and read full text papers to extract data.

RESULTS

Sixteen studies met eligibility criteria. Meta-analysis of three studies found that spine BMD was 0.100 g/cm(2) lower (95% CI, -0.110, -0.090 g/cm(2)) in 67 subjects with PKU, compared to 161 controls. Among six studies, 20% (53 of 263) of PKU subjects experienced clinical fractures. In the single study with controls, the fracture rate was 2.6 fold higher (95% CI, 1.1-6.1) after age 8 in PKU subjects, compared to healthy sibling controls. When considering a total of 12 studies in 412 subjects, nine or 75% of studies representing 71% of studied subjects reported no association between phenylalanine levels and BMD. Spine BMD is lower in PKU than control subjects, but only one study controlled for smaller body size. Existing studies suggest a clinical fracture rate of 20% among PKU subjects, but fracture rates in controls are lacking. Finally, existing data shows no consistent relationship between phenylalanine levels and BMD. Future studies are needed to clarify the etiology and health consequences of low BMD in PKU.

摘要

引言

我们的目的是系统回顾和分析已发表的关于苯丙酮尿症(PKU)患者骨矿物质密度(BMD)和骨折率的数据,以及BMD与苯丙氨酸水平之间的关系。

方法

我们检索了1966年1月至2013年11月期间的PubMed、CINAHL和Cochrane数据库,以查找关于PKU患者和对照受试者脊柱BMD或骨折的研究。我们排除了通过超声或外周定量计算机断层扫描评估骨骼健康的研究。两位作者对摘要进行了纳入审查,并阅读全文以提取数据。

结果

16项研究符合纳入标准。对三项研究的荟萃分析发现,与161名对照相比,67名PKU患者的脊柱BMD低0.100 g/cm²(95%CI,-0.110,-0.090 g/cm²)。在六项研究中,20%(263名中的53名)的PKU受试者发生了临床骨折。在有对照的单项研究中,与健康同胞对照相比,PKU受试者8岁后骨折率高2.6倍(95%CI,1.1-6.1)。在412名受试者的12项研究中,9项(占研究受试者的71%)报告苯丙氨酸水平与BMD之间无关联。PKU患者的脊柱BMD低于对照受试者,但只有一项研究对较小体型进行了校正。现有研究表明PKU受试者的临床骨折率为20%,但缺乏对照的骨折率数据。最后,现有数据显示苯丙氨酸水平与BMD之间没有一致的关系。需要进一步的研究来阐明PKU患者低BMD的病因和健康后果。

相似文献

3
Calcium and vitamin D for increasing bone mineral density in premenopausal women.钙和维生素 D 增加绝经前妇女的骨密度。
Cochrane Database Syst Rev. 2023 Jan 27;1(1):CD012664. doi: 10.1002/14651858.CD012664.pub2.
6
Steroidal contraceptives: effect on bone fractures in women.甾体避孕药:对女性骨折的影响
Cochrane Database Syst Rev. 2014 Jun 24;2014(6):CD006033. doi: 10.1002/14651858.CD006033.pub5.
7
Treatment for osteoporosis in people with beta-thalassaemia.β-地中海贫血患者骨质疏松的治疗。
Cochrane Database Syst Rev. 2023 May 9;5(5):CD010429. doi: 10.1002/14651858.CD010429.pub3.
9
Bisphosphonates for steroid-induced osteoporosis.双膦酸盐用于治疗类固醇诱导的骨质疏松症。
Cochrane Database Syst Rev. 2016 Oct 5;10(10):CD001347. doi: 10.1002/14651858.CD001347.pub2.

引用本文的文献

7
A New View of Bone Loss in Phenylketonuria.苯丙酮尿症中骨质流失的新观点。
Organogenesis. 2021 Oct 2;17(3-4):50-55. doi: 10.1080/15476278.2021.1949865. Epub 2021 Aug 25.

本文引用的文献

8
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.系统评价与Meta分析的首选报告项目:PRISMA声明。
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64. doi: 10.7326/0003-4819-151-4-200908180-00135. Epub 2009 Jul 20.
10
Phalangeal quantitative ultrasound in children with phenylketonuria: a pilot study.苯丙酮尿症患儿的指骨定量超声:一项初步研究。
Ultrasound Med Biol. 2008 Jul;34(7):1049-52. doi: 10.1016/j.ultrasmedbio.2007.12.013. Epub 2008 Mar 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验